The cannabinoid has been reclassified as a Schedule 5 medicine meaning that it can be dispensed more easily
News
Epidarex Capital closes life sciences venture fund at £102m
New UK fund underpinned by £50 million investment from the British Business Bank, via its Enterprise Capital Funds (ECF) programme
Research charities warn of funding cuts in coronavirus wake
The Association of Medical Research Charities and 151 of its members are calling on the UK government to match charity funded research for the next three years
Sanofi pays $300m upfront to expand deal with Translate Bio
The firms are working on the development of mRNA vaccines
Boehringer to sell stake in Hikma
Boehringer’s stake in the firm equates to around 16.4%
New coronavirus saliva test to be trialled in Southampton
Over 14,000 GP staff, other essential key workers and university staff and their households will participate in the first phase of the trial
MHRA extends access to Santhera’s DMD drug via the EAMS
The scientific opinion has been extended for one year while the drug is under regulatory review
Gilead to start testing an inhaled form of remdesivir
The firm is targeting an earlier stage in the treatment pathway for COVID-19
Last chance to register for the Patient Partnership Index 2020
Registration will close June 23 but entry forms can be submitted until July 3
GSK/Clover’s COVID-19 vaccine moves into human trials
The Phase I study is assessing use of a GSK pandemic adjuvant in combination with COVID-19 vaccine candidate SCB-2019
Novartis pulls plug on hydroxychloroquine trial
Study assessing its potential for COVID-19 discontinued due to feasibility of recruitment
ABPI consults on ‘new-look’ Code of Practice
A new version of the Code is expected to come into force in July 2021
EMA to consider expanding use of Merck/Pfizer’s Bavencio
The regulator will assess its safety and efficacy as a treatment for bladder cancer
Novo Nordisk’s AM833 shows early success in obesity trials
The firm is ‘encouraged’ by the performance of the drug, both as monotherapy and in combination with semaglutide
EU filing for CPP’s familial adenomatous polyposis drug
The drug prevented more than 90% of precancerous sporadic adenomas in trials
